Eli Lilly's Oral Obesity Drug Data Misses Expectations, Analyst Says

Eli Lilly's Oral Obesity Treatment Performance

• 💡 Eli Lilly's stock experienced a significant drop, but analyst Evan Seigerman believes it may be oversold, indicating the company was priced for perfection.
• 🎯 Expectations for the latest oral obesity treatment data were very high, with executives previously hinting at "WGO like efficacy".
• 📉 The new data showed 11% weight loss, falling short of the anticipated 15%+, which raises questions about the long-term strength of their franchise.

Comparison with Competitors and Market Dynamics

• 📊 Oral semaglutide from Novo Nordisk showed 16.6% weight loss with good tolerability, positioning it as a strong competitor.
• ⚖️ While 11% weight loss is still considered good, it may be more suited for maintenance after initial weight loss with injectables.
• 💊 The differences between the drugs are significant, including administration (oral vs. injectable), consumption restrictions (food effect), and manufacturing complexity.

Manufacturing and Cost Considerations

• 🔬 Eli Lilly's oral treatment involves manufacturing a larger peptide amount (25mg) compared to Novo Nordisk's injectable (2.4mg), leading to higher cost of goods.
• ⏰ A key advantage for Lilly's oral drug is its flexibility in dosing (can be taken anytime), unlike Novo's which requires fasting before and after administration.

Pricing and Market Competition

• 📉 The weight loss drug market is seeing pricing headwinds, with Eli Lilly offering larger rebates, impacting both companies.
• ⚠️ A CVS exclusive deal is expected to benefit Novo Nordisk and be a headwind for Eli Lilly in the latter half of the year.
• 🚫 Despite pricing concessions, Seigerman does not foresee a